See more : Givaudan SA (GVDNY) Income Statement Analysis – Financial Results
Complete financial analysis of Sandoz Group AG (SDZNY) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sandoz Group AG, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Tejnaksh Healthcare Limited (TEJNAKSH.BO) Income Statement Analysis – Financial Results
- Aryaman Financial Services Limited (ARYAMAN.BO) Income Statement Analysis – Financial Results
- PT Mitra Keluarga Karyasehat Tbk (MIKA.JK) Income Statement Analysis – Financial Results
- Australian Foundation Investment Company Limited (AFI.NZ) Income Statement Analysis – Financial Results
- Vanstar Mining Resources Inc. (VMNGF) Income Statement Analysis – Financial Results
Sandoz Group AG (SDZNY)
About Sandoz Group AG
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|
| Revenue | 9.98B | 8.86B | 8.79B | 9.04B |
| Cost of Revenue | 5.42B | 4.71B | 4.64B | 4.88B |
| Gross Profit | 4.56B | 4.15B | 4.15B | 4.16B |
| Gross Profit Ratio | 45.74% | 46.87% | 47.20% | 45.99% |
| Research & Development | 926.00M | 795.57M | 832.90M | 819.41M |
| General & Administrative | 0.00 | 22.50K | 0.00 | 0.00 |
| Selling & Marketing | 2.39B | 0.00 | 0.00 | 0.00 |
| SG&A | 2.39B | 22.50K | 1.94B | 2.00B |
| Other Expenses | 874.00M | 8.60M | 6.40M | 5.63M |
| Operating Expenses | 4.19B | 22.50K | 2.77B | 2.81B |
| Cost & Expenses | 9.60B | 22.50K | 7.41B | 7.69B |
| Interest Income | 31.00M | 7.64M | 4.57M | 2.82M |
| Interest Expense | 202.00M | 84.05M | 61.26M | 70.40M |
| Depreciation & Amortization | 525.00M | 437.42M | 447.08M | 650.46M |
| EBITDA | 857.00M | 1.68B | 1.83B | 1.99B |
| EBITDA Ratio | 8.59% | 0.00% | 20.77% | 22.03% |
| Operating Income | 375.00M | -22.50K | 1.38B | 1.34B |
| Operating Income Ratio | 3.76% | 0.00% | 15.69% | 14.83% |
| Total Other Income/Expenses | -245.00M | -137.00M | -179.20M | -677.68M |
| Income Before Tax | 130.00M | -22.50K | 1.20B | 662.66M |
| Income Before Tax Ratio | 1.30% | 0.00% | 13.65% | 7.33% |
| Income Tax Expense | 50.00M | 361.00 | 368.45M | 227.14M |
| Net Income | 77.00M | -22.86K | 830.15M | 433.64M |
| Net Income Ratio | 0.77% | 0.00% | 9.44% | 4.80% |
| EPS | 0.18 | 0.00 | 1.93 | 1.01 |
| EPS Diluted | 0.18 | 0.00 | 1.93 | 1.01 |
| Weighted Avg Shares Out | 429.90M | 431.00M | 431.00M | 431.00M |
| Weighted Avg Shares Out (Dil) | 431.20M | 431.00M | 431.00M | 431.00M |
The Daily Biotech Pulse: Sandoz Recalls Ulcer Drug, Anchiano Strikes Agreement With ADT Pharma, Proteon Announces Reverse Merger
Source: https://incomestatements.info
Category: Stock Reports